Skip to main content

Cancer: Screening

Question for Department of Health and Social Care

UIN HL13270, tabled on 29 January 2019

To ask Her Majesty's Government what assessment they have made of the implications for patient access to treatment for those continuing to rely on the National Tariff Payment System to fund cancer genomic tests under the Genomic Medicine Service in England.

Answered on

12 February 2019

Funding for cancer genomic testing is included under the National Tariff Payment System, excluding whole genome sequencing which NHS England is funding nationally, and is included within the healthcare resource group tariff payment for an individual patient. For example, epidermal growth factor receptor (EGFR) testing for lung cancer, along with oestrogen (positive/negative progesterone) receptor status and human epidermal growth factor receptor 2 (HER2) testing for breast cancer have been established tests within the National Health Service for a number of years.

Cancer genomic testing will continue to be funded by the National Tariff Payment System and the National Genomic Test Directory outlines the cancer genomic tests which will be delivered by the NHS in England.

Answered by

Department of Health and Social Care